News
STRO
3.895
+3.32%
0.125
Weekly Report: what happened at STRO last week (0415-0419)?
Weekly Report · 1d ago
CVAC, SBNY and CRMD are among after hour movers
Seeking Alpha · 6d ago
Weekly Report: what happened at STRO last week (0408-0412)?
Weekly Report · 04/15 12:01
Weekly Report: what happened at STRO last week (0401-0405)?
Weekly Report · 04/08 12:07
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen S.A. Is a pharmaceutical company focused on oncology, rare disease and neuroscience. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Last week, Ipsen announced a deal with Sutro Biopharma to develop a pre-clinical antibody drug candidate in ovarian cancer. Ipsen offers a more de-risked opportunity, Sutro has explosive growth potential.
Seeking Alpha · 04/05 22:31
Sutro Biopharma Price Target Cut to $11.00/Share From $12.00 by Piper Sandler
Dow Jones · 04/03 15:45
Piper Sandler Reiterates Overweight on Sutro Biopharma, Lowers Price Target to $11
Benzinga · 04/03 15:35
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 04/03 14:16
Sutro Biopharma Price Target Maintained With a $10.00/Share by Oppenheimer
Dow Jones · 04/03 14:16
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Benzinga · 04/03 14:06
Sutro Biopharma Is Maintained at Buy by Truist Securities
Dow Jones · 04/03 13:43
Sutro Biopharma Price Target Cut to $18.00/Share From $25.00 by Truist Securities
Dow Jones · 04/03 13:43
Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
Benzinga · 04/03 13:32
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Dow Jones · 04/03 12:34
JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Benzinga · 04/03 12:23
Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)
TipRanks · 04/03 11:06
Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline
TipRanks · 04/03 04:35
SUTRO BIOPHARMA INC <STRO.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $18 FROM $25
Reuters · 04/03 03:56
SUTRO BIOPHARMA INC <STRO.O>: PIPER SANDLER CUTS TARGET PRICE TO $11 FROM $12
Reuters · 04/03 03:42
What's Going On With Sutro Biopharma (STRO) Stock?
Sutro Biopharma Inc announced pricing of an underwritten offering of 14,478,764 shares of its common stock at $5.18 per share. The company is aiming to raise approximately $75 million. Sutro shares are trading lower by 2.8% in Tuesday's session.
Benzinga · 04/02 16:46
More
Webull provides a variety of real-time STRO stock news. You can receive the latest news about Sutro Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About STRO
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.